Leucine-rich repeat flightless-interacting protein 1 (LRR FLII-interacting protein 1), also known as GC-binding factor 2 or TAR RNA-interacting protein, and encoded by the gene name LRRFIP1 or GCF2 or TRIP, is a transcriptional repressor that mainly plays a cytoskeletal role. LRRFIP1 is primarily localized in the cytoplasm and preferentially binds to GC-rich dsDNA, but will also bind directly to dsRNA as well. The RNA binding domain encompasses a lysine-rich motif. LRRFIP1 interacts with the mammalian Flightless I (Fli-I) and is a key component in the cytoskeletal regulation of platelet function. LRRFIP1 and the related protein LRRFIP2 may modulate canonical WNT signaling and mediate the IRF3-induced production of type I interferon via a β-catenindependent pathway.

~85 kDa observed. Uncharacterized bands may be observed in some lysate(s). Uniprot describes 4 isoforms produced by alternative splicing ranging between ~73 kDa and ~89 kDa

KLH-conjugated synthetic peptide corresponding to human LRRFIP1.

Anti-LRRFIP1 Antibody detects level of LRRFIP1 & has been published & validated for use in LRRFIP1.

Research Category
Cell Structure

Research Sub Category
Cytoskeleton

Antigen Affinity Purified

Purified rabbit polyclonal in buffer containing PBS with up to 0.1% sodium azide.

Stable for 1 year at 2-8°C from date of receipt.

Evaluated by Western Blotting in human colon tissue lysate.

Western Blotting Analysis: 1 μg/mL of this antibody detected LRRFIP1 in human colon tissue lysate.

Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.